2023 World Conference on Lung Cancer (Posters)-EP12.02. Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs

EP12.02. Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs - PDF(Abstract)

Back to course

Pdf Summary

This presentation at WCLC 2023 focused on the treatment patterns and economic burden of brain metastases (BMs) in patients with ALK non-small cell lung cancer (NSCLC) receiving ALK tyrosine kinase inhibitors (TKIs). Brain metastases occur at a high incidence among patients with metastatic ALK NSCLC and remain a significant source of morbidity and mortality, despite the availability of CNS-active ALK TKIs. <br /><br />The study conducted a retrospective analysis using three US claims databases from July 2017 to October 2022. Adults newly diagnosed with metastatic ALK NSCLC with BM were identified using a combination of diagnosis codes and pharmacy records. The primary cohort included patients with a 30-day enrollment period before and after the BM diagnosis date, while the secondary cohort focused on economic outcomes during a 2-month pre- and post-BM period.<br /><br />Results showed that 41.7% of patients received an ALK TKI prior to their first BM diagnosis, with alectinib being the most common (30%). Treatment patterns post-BM diagnosis varied, including changes in systemic therapy and brain-directed radiotherapy. The median total per-patient-per-month medical costs during the 30-day pre- and post-BM diagnosis period were relatively high, ranging from $11,380 to $23,067 across the different databases.<br /><br />The study highlighted the need for therapeutic strategies to delay or prevent BM occurrence and reduce its burden in patients with ALK NSCLC. The findings emphasized the varied treatment approaches and the high cost burden associated with BM diagnosis. The authors suggested the importance of developing strategies in the first-line setting to address these challenges and improve outcomes for patients with ALK NSCLC and BM.

Asset Subtitle

Hannah Le

Meta Tag

Speaker Hannah Le

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

brain metastases

ALK non-small cell lung cancer

tyrosine kinase inhibitors

retrospective analysis

treatment patterns

economic burden

medical costs

systemic therapy

BM occurrence

first-line setting